{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:12 23:20:22.323",
            "Expression": "mesenchymal allo-APZ2-CVU",
            "NStudiesAvail": 430639,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Andreas Kerstan, Dr."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Complete wound closure at Week 18 already persisting for at least two weeks will be evaluated.",
                              "All AEs occurring during the clinical trial will be registered, documented and evaluated."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Complete wound closure at Week 18 already persisting for at least two weeks",
                              "Assessment of adverse event (AE) occurrence"
                        ],
                        "NCTId": [
                              "NCT04971161"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Andreas Kerstan, Dr."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 25, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Percentage of wound size reduction at Week 12, or last available post-baseline measurement of Weeks 6, 8 or 10 if the Week 12 measurement is missing (last observation carried forward [LOCF]).",
                              "All AEs occurring during the clinical trial will be registered, documented and evaluated."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percentage of wound size reduction",
                              "Assessment of adverse event (AE) occurrence"
                        ],
                        "NCTId": [
                              "NCT03257098"
                        ]
                  }
            ]
      }
}